Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

In Q2 2025, the global pharma sector experienced a decline in M&A activity, with deals worth $32.9 billion, down 11.6% from Q1. Deal volume fell 12.8% to 130. Oncology led with 51 deals. Discover key ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Momentum returns as biotech enters next phase ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi’s latest earnings call reflects a positive outlook for the company, marked by strong sales growth, strategic acquisitions, and a commitment to sustainability. Despite some challenges, such as ...

The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount.

SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...